Imagen de Portada

Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Jamy D. Ard, Young‐Rock Hong, Gary D. Foster, Adam Medcalf, Spencer Nadolsky, Michelle I. Cardel
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Obesity
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Nutritional considerations with antiobesity medications
por: Jaime P. Almandoz, et al.
Publicado: (2024)

The latest evidence and clinical guidelines for use of meal replacements in very‐low‐calorie diets or low‐calorie diets for the treatment of obesity
por: Shenelle A. Edwards‐Hampton, et al.
Publicado: (2024)

Efficacy of Oral Antiobesity Medications With Versus Without Adjunct Behavioral Weight Management Treatment
por: Rebecca A. Jones, et al.
Publicado: (2026)

Net prices of new antiobesity medications
por: Inmaculada Hernandez, et al.
Publicado: (2024)

Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study
por: Lee M. Kaplan, et al.
Publicado: (2025)

Response to “Nutritional considerations with antiobesity medications”
por: Shaminie J. Athinarayanan
Publicado: (2024)

Response to “Nutritional considerations with antiobesity medications”
por: Gabriela de Souza Bett, et al.
Publicado: (2024)

Psychosocial Outcomes in Telemedicine and Long‐Acting Incretin‐Specific Behavioral Intervention
por: Leslie J. Heinberg, et al.
Publicado: (2026)

Virtual Weight Management and Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Randomized Controlled Trial
por: Peter T. Katzmarzyk, et al.
Publicado: (2026)

Adolescent experiences of weight‐related communication: Sociodemographic differences and the role of parents
por: Leah M. Lessard, et al.
Publicado: (2024)

Meta‐analysis and machine learning reveal the antiobesity effects of melatonin on obese rodents
por: Yuying Li, et al.
Publicado: (2024)

Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study
por: Leslie J. Heinberg, et al.
Publicado: (2025)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
por: Jason M. Samuels, et al.
Publicado: (2024)

Anti‐obesity treatment preferences of healthcare providers and people living with obesity: A survey‐based study
por: Carel W. Le Roux, et al.
Publicado: (2024)

Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study
por: Jamy D. Ard, et al.
Publicado: (2025)

Pretreatment predictors of weight loss in a 12‐month behavioral obesity treatment: a signal detection analysis of DIETFITS
por: Michele L. Patel, et al.
Publicado: (2025)

Response to Hayashi et al.
por: Corby K. Martin, et al.
Publicado: (2025)

GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
por: Kristen M. Beavers, et al.
Publicado: (2024)

Clarification of our response to “The importance of diversity in Obesity articles”
por: Michelle Cardel, et al.
Publicado: (2024)

Impact of eating behavior on 24‐month weight change after treatment of severe obesity—A clinical prospective cohort study
por: Sofia Björkman, et al.
Publicado: (2024)

The vices and virtues of medical models of obesity
por: Jonathan Sholl, et al.
Publicado: (2024)

Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE)
por: Aleksandrina Ruseva, et al.
Publicado: (2024)

The effects of anti‐obesity medications on bone metabolism: A critical appraisal
por: Athanasios D. Anastasilakis, et al.
Publicado: (2025)

Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real‐world UK data: A clinical evaluation of a multi‐ethnic population
por: Laurence J. Dobbie, et al.
Publicado: (2024)

Response to the Letter to the Editor by Bett et al.
por: Jaime P. Almandoz, et al.
Publicado: (2024)

Response to the Letter to the Editor by Athinarayanan
por: Jaime P. Almandoz, et al.
Publicado: (2024)

Exploring the Role of Internalized Weight Bias as a Metric of Cumulative Social Disadvantage Among People With Obesity or Overweight: Insights From the OBSERVE Study
por: Jamy Ard, et al.
Publicado: (2025)

Determinants of adherence to obesity medication: A narrative review
por: Arya M. Sharma, et al.
Publicado: (2025)

Measurement and evaluation of community engagement in complex, chronic medical conditions: HIV and obesity as exemplar conditions
por: Andrew D. Brown, et al.
Publicado: (2025)

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
por: Lauren Wilson, et al.
Publicado: (2026)

Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study
por: Testimony Ipaye, et al.
Publicado: (2025)

Primary care perspectives on prescribing anti‐obesity medication for adolescents
por: Rutha Chivate, et al.
Publicado: (2024)

The role of incretin receptor agonists in the treatment of obesity
por: Thomas Forst, et al.
Publicado: (2024)

When can weekly anti‐obesity peptides be used for monthly administration?
por: Daniel V. Santi
Publicado: (2024)

Cost‐effectiveness analysis of individual‐level obesity treatment in paediatrics: A scoping review
por: Ashwin Dhillon, et al.
Publicado: (2024)

Efficacy of an mHealth‐delivered behavioral intervention on weight loss and cardiometabolic risk in African American postpartum people with overweight or obesity: the SnapBack randomized controlled trial
por: Sharon J. Herring, et al.
Publicado: (2024)

Patient perceptions of success in obesity treatment: An IMI2 SOPHIA study
por: E. Farrell, et al.
Publicado: (2024)

Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial
por: Faith Anne N. Heeren, et al.
Publicado: (2025)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
por: Flora Lambert, et al.
Publicado: (2025)

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
por: Sean Wharton, et al.
Publicado: (2024)